Abstract
In The Lancet Infectious Diseases, Sean Bennett and colleagues1 describe the safety and immunogenicity of PXVX0317, a novel vaccine for the prevention of chikungunya infection based on an adjuvanted virus-like particle (VLP). Chikungunya virus (CHIKV) is an arthropod-borne alphavirus transmitted by mosquitoes and causes a febrile illness characterised by severe arthralgia that can lead to chronic disability.2 There is no approved specific antiviral therapy or vaccine for chikungunya infection. Outbreaks of chikungunya have occurred worldwide—typically during tropical rainy seasons—for example, the 2013–14 outbreak in the Americas which led to more than 1·2 million cases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
